<DOC>
	<DOCNO>NCT01970345</DOCNO>
	<brief_summary>The propose project pilot use IGF-1 novel treatment core symptom autism . We use double-blind , placebo-controlled crossover trial design five child autism evaluate impact IGF-1 treatment autism-specific impairment socialization , language , repetitive behavior . We expect provide evidence safety feasibility IGF-1 ameliorate social withdrawal child Autistic Disorder . Further , expect demonstrate IGF-1 associate improvement secondary outcome social impairment , language delay , repetitive behavior , well functional outcome global severity .</brief_summary>
	<brief_title>A Pilot Treatment Study Insulin-Like Growth Factor-1 ( IGF-1 ) Autism Spectrum Disorder</brief_title>
	<detailed_description>IGF-1 FDA approve , commercially available compound cross blood-brain barrier beneficial effect synaptic development promote neuronal cell survival , synaptic maturation , synaptic plasticity . IGF-1 effective reversing mouse neuronal model Rett syndrome Phelan McDermid syndrome , single gene cause ASD may therefore effective treat autism spectrum disorder ( ASD ) broadly .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Meet DSM5 criterion Autism Spectrum Disorder confirm Autism Diagnostic InterviewRevised ( ADIR ) Autism Diagnostic Observation Schedule Generic ( ADOSG ) Children age 512 year age Language delay ( lack fluent phrase speech ) reflect use ADOS Module 1 2 Must stable medication regimen least three month prior enrollment , assume concomitant medication safe use IGF1 Closed epiphysis Active suspect neoplasia Intracranial hypertension Hepatic insufficiency Renal insufficiency Cardiomegaly/valvulopathy History allergy IGF1 Patients comorbid condition deem medically compromise tolerate risk experimental treatment IGF1</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Autism Spectrum Disorder</keyword>
	<keyword>IGF-1</keyword>
</DOC>